AMP-activated protein kinase modulators: a patent review (2006-2010)

被引:21
作者
Yun, Hee
Ha, Joohun [1 ]
机构
[1] Kyung Hee Univ, Med Res Ctr, Seoul 130701, South Korea
关键词
AMPK; AMPK modulators; cancer; metabolic disorders; pharmaceutical compounds; FATTY-ACID OXIDATION; HER-2/NEU TRANSGENIC MICE; PROSTATE-CANCER CELLS; PANCREATIC BETA-CELLS; INDUCED HEART-FAILURE; N-TERMINAL KINASE; ANTIDIABETIC DRUG; GLUCOSE-METABOLISM; SKELETAL-MUSCLE; AICA-RIBOSIDE;
D O I
10.1517/13543776.2011.577069
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Introduction: AMPK is a key player in the regulation of energy balance at both the cellular and whole-body levels, placing it at the center stage in studies of metabolic disorders. Recently, AMPK has also been identified as a potential target for either therapy or prevention of some types of cancer. Thus, identification of AMPK modulators for possible use as novel therapeutic drugs, both for treatment of metabolic disorders and cancer, will have a high commercial potential. Areas covered: This review covers the structures and activities of AMPK modulators described in the patent literature since 2006. The patents reviewed include those for direct and/or indirect activators of AMPK, and novel pharmaceutical compounds with potential for use in the prevention and/or treatment of metabolic disorders, and cancer targeting AMPK. Expert opinion: Targeting of AMPK appears to be an attractive strategy in the treatment of metabolic disorders. However, some detrimental effects of AMPK have also been reported, including a possible tumor-promoting effect in some settings and a heart disease-causing effect. Moreover, activation of AMPK in the hypothalamus may cause undesired consequences, such as an increase in feeding and body weight gain. These effects, therefore, must be carefully assessed for the development of therapeutic drugs targeting AMPK.
引用
收藏
页码:983 / 1005
页数:23
相关论文
共 148 条
[1]   Stimulation of AMP-activated protein kinase (AMPK) is associated with enhancement of Glut1-mediated glucose transport [J].
Abbud, W ;
Habinowski, S ;
Zhang, JZ ;
Kendrew, J ;
Elkairi, FS ;
Kemp, BE ;
Witters, LA ;
Ismail-Beigi, F .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2000, 380 (02) :347-352
[2]  
AGIOS PHARMACEUTICAL, 2010, Patent No. 2010114922
[3]   Exercise in rats does not alter hypothalamic AMP-activated protein kinase activity [J].
Andersson, U ;
Treebak, JT ;
Nielsen, JN ;
Smith, KL ;
Abbott, CR ;
Small, CJ ;
Carling, D ;
Richter, EA .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 329 (02) :719-725
[4]   AMP-activated protein kinase plays a role in the control of food intake [J].
Andersson, U ;
Filipsson, K ;
Abbott, CR ;
Woods, A ;
Smith, K ;
Bloom, SR ;
Carling, D ;
Small, CJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (13) :12005-12008
[5]   Liver adenosine monophosphate-activated kinase-α2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin [J].
Andreelli, F ;
Foretz, M ;
Knauf, C ;
Cani, PD ;
Perrin, C ;
Iglesias, MA ;
Pillot, B ;
Bado, A ;
Tronche, F ;
Mithieux, G ;
Vaulont, S ;
Burcelin, R ;
Viollet, B .
ENDOCRINOLOGY, 2006, 147 (05) :2432-2441
[6]   Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice [J].
Anisimov, VN ;
Egormin, PA ;
Bershtein, LM ;
Zabezhinskii, MA ;
Piskunova, TS ;
Popovich, IG ;
Semenchenko, AV .
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2005, 139 (06) :721-723
[7]   Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice [J].
Anisimov, VN ;
Berstein, LM ;
Egormin, PA ;
Piskunova, TS ;
Popovich, IG ;
Zabezhinski, MA ;
Kovalenko, IG ;
Poroshina, TE ;
Semenchenko, AV ;
Provinciali, M ;
Re, F ;
Franceschi, C .
EXPERIMENTAL GERONTOLOGY, 2005, 40 (8-9) :685-693
[8]   AMP-activated protein kinase in the heart - Role during health and disease [J].
Arad, Michael ;
Seidman, Christine E. ;
Seidman, J. G. .
CIRCULATION RESEARCH, 2007, 100 (04) :474-488
[9]   The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level [J].
Ben Sahra, I. ;
Laurent, K. ;
Loubat, A. ;
Giorgetti-Peraldi, S. ;
Colosetti, P. ;
Auberger, P. ;
Tanti, J. F. ;
Le Marchand-Brustel, Y. ;
Bost, F. .
ONCOGENE, 2008, 27 (25) :3576-3586
[10]   Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug? [J].
Ben Sahra, Issam ;
Le Marchand-Brustel, Yannick ;
Tanti, Jean-Francois ;
Bost, Frederic .
MOLECULAR CANCER THERAPEUTICS, 2010, 9 (05) :1092-1099